Skip to main content

Table 1 Characteristics of the study cohort

From: The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study

 

First Primary Cancers

Second Primary Cancers

N

%

N

%

Sex

 Males

155,214

50.1

19,811

58.6

 Females

154,899

49.9

13,982

41.4

Age at diagnosis

 15–49 years

54,930

17.7

1250

3.7

 50–64 years

93,939

30.3

6708

19.9

 65 years and over

161,244

52.0

25,835

76.5

Period of diagnosis

 1981–1984

27,063

8.7

411

1.2

 1985–1989

39,184

12.6

1971

5.8

 1990–1994

47,624

15.4

3364

10.0

 1995–1999

57,764

18.6

4724

14.0

 2000–2004

67,145

21.7

6566

19.4

 2005–2009

71,333

23.0

8635

25.6

 2010–2014

n.a*

 

8122

24.0

Follow-up interval

 6 month to less than 1 year

n.a.**

 

2098

6.2

 1 years to less than 5 years

n.a.**

 

12,532

37.1

 5 years to less than 10 years

n.a.**

 

10,011

29.6

 10 years and longer

n.a.**

 

9152

27.1

Type of primary cancer

 Cavity & Pharynx (C00-C14)

8465

2.7

1565

4.6

 Oesophagus (C15)

3055

1.0

785

2.3

 Stomach (C16)

7663

2.5

1056

3.1

 Colorectal (C18-C20)

35,949

11.6

4353

12.9

 Extrahepatic Bile Ducts (C22)

2780

0.9

768

2.3

 Pancreas (C25)

4534

1.5

1267

3.7

 Larynx (C32)

2575

0.8

367

1.1

 Lung (C33-C34)

24,539

7.9

5152

15.2

 Melanoma (C43)

17,794

5.7

1662

4.9

 Breast female (C50)

59,453

19.2

2597

7.7

 Cervix uteri (C53)

4080

1.3

125

0.4

 Corpus uteri & NOS (C54-C55)

9710

3.1

876

2.6

 Ovary (C56)

6067

2.0

530

1.6

 Prostate (C61)

48,311

15.6

3694

10.9

 Testis (C62)

4912

1.6

36

0.1

 Kidney (C64)

6210

2.0

812

2.4

 Bladder (C67)

9801

3.2

1387

4.1

 Brain & Central Nerves (C70-C72)

4072

1.3

403

1.2

 Thyroid (C73)

4360

1.4

414

1.2

 Hodgkin Lymphoma (C81)

2481

0.8

123

0.4

 non-Hodgkin Lymphoma (C82-C86, C96)

11,340

3.7

1301

3.8

 Multiple Myeloma (C90)

4298

1.4

487

1.4

 Leukemia (C91-C95)

7933

2.6

1062

3.1

 Others

19,731

6.4

2971

8.8

All cancers

310,113

100.0

33,793

100.0

  1. * n.a.: not applicable; the study cohort includes first primary cancers of the period 1981–2009
  2. **n.a.: not applicable; follow-up interval refers to the interval between first and second primary cancer